Navigation Links
John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
Date:9/26/2013

HACKENSACK, N.J., Sept. 26, 2013 /PRNewswire/ -- Andre Goy, M.D., M.S., Chairman and Director of John Theurer Cancer Center and Chief of the Lymphoma Program, has just published two important papers in relapsed/refractory mantle-cell lymphoma (MCL) in the Journal of Clinical Oncology and New England Journal of Medicine. MCL is a difficult subtype of non-Hodgkin lymphoma, where patients often become chemoresistant after responding to initial therapy.

Dr. Goy, an international expert in the field, led the lenalidomide global pivotal trial known as MCL-001 or EMERGE trial. Lenalidomide belongs to a category of immunomodulators that is first-in-class approved for lymphoma. This Phase II study showed that lenalidomide induced rapid and prolonged response in patients who were heavily pretreated regardless of the number of their prior regimens and with a median duration of response of more than 16 months. Many of these patients had also been refractory to their last prior therapy. The EMERGE trial results were published in the leading Journal of Clinical Oncology ("Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study" JCO September 2013).

"This trial led to the recent approval by the FDA of lenalidomide as the first oral compound available for that disease addressing a definite unmet need for these patients," said Andre Goy, M.D., M.S., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "Lenalidomide is only the second drug ever approved for the treatment of mantle-cell lymphoma."

The second study was published in the New England Journal of Medicine a few weeks ago in collaboration
'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Revolutionary Natural Sunscreen That Can Reverse Wrinkles, Fine Lines, Sagging Skin, Laugh Lines And Potentially Reverse Cancer Cell Formation With Anti-Aging And Anti-Cancer Forming Natural Ingredients Now Available From Rejuve MD
2. New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying
3. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
4. Laser-Proton Therapy Working Group Takes Second Look at Ways to Lower Cost of Advanced Cancer Treatment
5. APPLIED INTEGRIN SCIENCES, INC. LAUNCHES CROWDFUNDING CAMPAIGN TO RAISE FUNDS FOR ITS CANCER DRUG DEVELOPMENT PROGRAM
6. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
7. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
8. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
9. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
10. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
11. Study Suggests that a Single Session of Stereotactic Body Radiation Therapy (Lung Radiosurgery) is a Promising Approach for Treating Inoperable Early-Stage Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Roche,s ... conspicuously high-growth market segment in hematology testing, according ... said that Roche,s recent unveiling of its Bloodhound digital ... cobas m 511 hematology analyzer – ... capture growth enjoyed by current leader CellaVision, but ...
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
(Date:7/2/2015)... Mass. , July 2, 2015   ... and European retinal specialists identify less frequent dosing ... edema (DME), due to the burden on both ... anti-vascular endothelial growth factor (VEGF) injections, which are ... Allergan/Molecular Partners, abicipar pegol, which is in development ...
Breaking Medicine Technology:Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3
... 2011 Reportlinker.com announces that a new ... catalogue: U.S. Urinary Incontinence ... This research study covers ... market. The urinary incontinence device market which ...
... NEW YORK, June 22, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ... forecasts for CROs globally, by phase and ...
Cached Medicine Technology:Reportlinker Adds U.S. Urinary Incontinence Devices 2Reportlinker Adds U.S. Urinary Incontinence Devices 3Reportlinker Adds U.S. Urinary Incontinence Devices 4Reportlinker Adds Global CRO Market: Quantitative Assessment 2Reportlinker Adds Global CRO Market: Quantitative Assessment 3
(Date:7/2/2015)... ... ... LIFX ” was featured on NewsWatch as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... According to the U.S. Department of Energy, it’s very important to use energy-efficient light ...
(Date:7/2/2015)... GA (PRWEB) , ... July 02, 2015 , ... ... sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks were ... experts and athletic trainers. Their significant popularity has inspired four new, fun shades ...
(Date:7/2/2015)... ... 02, 2015 , ... Six months ahead of his 80th birthday, Don Stevenson ... and money for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in ... D.C. by mid-September. He left Glasgow, Mont. yesterday morning and is making his way ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com ... a passion for social fitness. Built to function as a lifestyle community, Active Bunch ... them the opportunity to network, meet, and participate in discussions or group events. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... (NPWT) - pipeline review 2015” provides comprehensive information on the pipeline products ... report on negative pressure wound therapy (NPWT) with 22 market data tables ...
Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4
... or no sunscreen in spite of staying under direct sunlight ... sports spend a significant amount of time practicing and competing ... they are spending so much time in the sun, they ... of them regularly use any form of sunscreen, according to ...
... Immunization (IFFIm) will be providing life saving vaccines for ... project costing $4 billion to be funded by the ... the scheme, the International Finance Facility for Immunization (IFF), ... over the next 10 years and another five million ...
... daily stress in their life have less risk of developing ... in the British Medical Journal. The study was conducted in ... The estrogen which is responsible for growth ... have found that stress reduced the production of oestrogen and ...
... In a study, published in the recent issue of The ... Hospital, Michigan, had concluded that obesity is a risk factor ... are below the age of 40years.// ,Since 1927, ... fatal pulmonary embolism (PE). Because of the high proportion of ...
... a married couple in West Bengal. The duo preferred to ... everyday. ,In an act driven// by social ostracism, a 29-year-old ... hanged himself in the Durgapur industrial town of south Bengal's ... Sarkar were a happy couple since their love marriage four ...
... in people may accelerate the heart conditions by releasing the ... study of 32 people with heart failure, the 14 patients ... of this protein in their blood. ,The protein, tumor ... family of proteins called cytokines, chemical messengers that are mobilized ...
Cached Medicine News:Health News:People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings 2Health News:European Countries To Fund $4 Billion For Vaccination For Poor Children’ 2
... the "Consensus Concept" approach to design by ... of a Scientific Advisory Board. The result ... state-of-the-art features. Consensus Knee implants are designed ... and allow near normal kinematics. The components ...
Profix total knee system is intended for cemented use only....
Cruciate Retaining, Posterior Stabilized and Constrained Components....
... solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
Medicine Products: